Brentuximab vedotin for treatment of systemic T-cell lymphoma

Abstract

Introduction: Brentuximab vedotin (BV) is an antibody-drug conjugate that consists of the anti-CD30 monoclonal antibody conjugated with monomethyl auristatin E. BV has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. These two diseases certainly show high levels of CD30 expression. Of interest, however, BV has shown activities in other lymphomas that express low or even undetectable levels of CD30.

Areas covered: We update and summarize a recent report of BV in T-cell lymphomas.

Expert opinion: Single-agent BV showed overall response rates of 54% in angioimmunoblastic T-cell lymphoma and 33% in peripheral T-cell lymphoma not otherwise specified in the recent trial. The efficacy of BV in T-cell lymphomas with low or undetectable CD30 expression was promising. The use of BV in combination with chemotherapy as frontline treatment is currently being investigated. Future studies should include correlative biomarker analysis and optimization of combination therapies.

Keywords::

• brentuximab vedotin
• CD30
• monomethyl auristatin E
• peripheral T-cell lymphoma

Acknowledgements

The authors would like to thank Tamara Locke of the MD Anderson Cancer Centre for scientific editing of the paper for consistencies and grammar.